BioCentury
ARTICLE | Top Story

Alder, Amgen up after migraine data

May 16, 2015 1:13 AM UTC

Shares of Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) and Amgen Inc. (NASDAQ:AMGN) rose after the companies reported data for migraine therapies targeting calcitonin gene-related peptide ( CGRP) at the Congress of the International Headache Society in Valencia, Spain.

Alder jumped to an all-time high of $40.04 before closing up $4.35 (12%) to $39.84 for the largest percentage gain among companies in the BioCentury 100 on Friday after reporting six-month follow-up data from a Phase II study of ALD403. ...